Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Alexion Pharmaceuticals Inc. (ALXN)

114.43   1.97 (1.75%) 10-01 08:48
Open: 113.13 Pre. Close: 112.46
High: 115 Low: 112.85
Volume: 1,655,430 Market Cap: 25,080M
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees. The firm is focused on the development and commercialization of therapeutic products. The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 115.164 - 115.809 115.809 - 116.4
Low: 111.131 - 111.983 111.983 - 112.763
Close: 113.198 - 114.431 114.431 - 115.559

Technical analysis

as of: 2020-09-30 4:38:32 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 141.11     One year: 164.81
Support: Support1: 109.49    Support2: 102.50
Resistance: Resistance1: 120.81    Resistance2: 141.11
Pivot: 112.36
Moving Average: MA(5): 113.33     MA(20): 112.01
MA(100): 108.85     MA(250): 104.91
MACD: MACD(12,26): 1.74     Signal(9): 1.79
Stochastic oscillator: %K(14,3): 57.77     %D(3): 58.18
RSI: RSI(14): 57.24
52-week: High: 121.50  Low: 72.67  Change(%): 15.4
Average Vol(K): 3-Month: 188889  10-Days: 206064

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
ALXN has closed below upper band by 33.7%. Bollinger Bands are 3.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 30 Sep 2020
Alexion Pharmaceuticals Inc. (ALXN) is primed for evolution with the beta value of 1.31 - The InvestChronicle

Wed, 30 Sep 2020
Alexion Pharmaceuticals Inc. (ALXN): Skating on Thin Ice? We Know the Answer - The News Heater

Wed, 30 Sep 2020
Short Interest On Alexion Pharmaceuticals, Inc. (ALXN) Might Be Rising - Invest Million

Tue, 29 Sep 2020
Alexion Pharmaceuticals Inc. (ALXN) is 5.85% away from 50-day simple Moving Average despite all headwinds - News Daemon

Fri, 25 Sep 2020
Alexion Pharmaceuticals Inc. (ALXN) Reveals an Earnings Mystery -

Mon, 21 Sep 2020
Alexion Pharmaceuticals Inc. (ALXN) Open at price of $114.39: A Brand-New Opportunity for Investors - News Daemon

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 219
Shares Float (M) 219
% Held by Insiders 0.30
% Held by Institutions 95.39
Shares Short (K) 4,840
Shares Short P. Month (K) 4,410

Stock Financials

EPS 3.810
EPS Est This Year 5.620
EPS Est Next Year 7.130
Book Value (p.s.) 47.880
Profit Margin 15.28
Operating Margin 46.40
Return on Assets (ttm) 10.3
Return on Equity (ttm) 8.2
Qtrly Rev. Growth 20.1
Gross Profit (p.s.) 20.988
Sales Per Share 25.277
EBITDA (p.s.) 13.277
Qtrly Earnings Growth
Operating Cash Flow (M) 2,460
Levered Free Cash Flow (M) 1,690

Stock Valuations

PE Ratio 30.03
PEG Ratio 0.74
Price to Book value 2.39
Price to Sales 4.53
Price to Cash Flow 10.19

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.